DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
>
> This Story

Forward Printable StoryPrint Comment

 

 

Ultrasound Homepage

MITA applauds new research showing effectiveness of high intensity focused ultrasound in treating prostate cancer

Hologic's Viera, portable breast ultrasound, enter U.S. and European marketplace

Visura Technologies receives FDA nod for the TEE Camera Assist Device System

Hitachi Healthcare Americas unveils the latest in cardiovascular ultrasound and reporting at ASE 2018

Konica Minolta launches portable ultrasound with one-touch image optimization for improved workflow and diagnostic efficiency

Konica Minolta launches portable ultrasound with one-touch image optimization for improved workflow and diagnostic efficiency

AUE now offers Sonostar Wireless probes for sports medicine, EMS, and veterinary markets

Siemens Healthineers launches Acuson Sequoia to address industry challenges in ultrasound imaging

Fujifilm brings enterprise solutions for echocardiography, vascular, and point-of-care ultrasound to ASE 2018

SonoVue approved in China for intravesical use in ultrasonography of the excretory tract to detect vesicoureteral reflux

Focused ultrasound used to improve effects of cancer drugs

Press releases may be edited for formatting or style
Researchers have made a breakthrough in more precisely targeting drugs to cancers. Using ultrasound and lipid drug carriers (liposomes), a multi-disciplinary team of biomedical engineers, oncologists, radiologists and anaesthetists at the University of Oxford have developed a new way to improve the targeting of cancer drugs to tumours.

The new technology has been used in humans for the very first time, with ultrasound remotely triggering and enhancing the delivery of a cancer drug to the tumour.

Story Continues Below Advertisement

Breast Health Solutions

Innovative AI software solutions built on deep learning for breast tomosynthesis, breast density and 2D mammography. Learn more>



'Reaching therapeutic levels of cancer drugs within a tumour, while avoiding side effects for the rest of the body is a challenge for all cancer drugs, including small molecules, antibodies and viruses,' said Professor Constantin Coussios, Director of the Oxford Centre for Drug Delivery Devices (OxCD3) and of the Institute of Biomedical Engineering at the University of Oxford. 'Our study is the first to trial this new technique in humans, and finds that it is possible to safely trigger and target the delivery of chemotherapy deep within the body from outside the body using focussed ultrasound. Once inside the tumour, the drug is released from the carrier, supplying a higher dose of chemotherapy directly to the tumour, which may help to treat tumours more effectively for the same or a lower systemic dose of the drug.'

Published in The Lancet Oncology journal, the 10-patient phase 1 clinical trial used focussed ultrasound from outside the body to selectively heat liver tumours and trigger drug release from heat-sensitive carriers, known as thermosensitive liposomes. Building on over a decade of preclinical studies, the study demonstrated the ultrasound technique to be feasible, safe, and capable of increasing drug delivery to the tumour between two-fold and ten-fold in the majority of patients. Ongoing research worldwide is investigating the applicability of this technique to other tumour types, and future research could explore the combination of ultrasound with other drugs.

All 10 patients treated had inoperable primary or secondary tumours in the liver and had previously received chemotherapy. The procedure was carried out under general anaesthesia and patients received a single intravenous dose of 50 mg/m2 of doxorubicin encapsulated within low-temperature-sensitive liposomes (ThermoDox®, Celsion Corporation, USA). The target tumour was selectively heated to over 39.5o C using an approved ultrasound-guided focussed ultrasound device (JC200, Chongqing HAIFU, China) at the Early Phase Clinical Trials Unit at the Churchill Hospital in Oxford. In six out of 10 patients, the temperature at the target tumour was monitored using a temporarily implanted probe, whilst in the remaining four patients ultrasonic heating was carried out non-invasively.
  Pages: 1 - 2 >>

Ultrasound Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED